These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 20923857)

  • 21. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
    Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
    Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
    Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
    Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
    Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
    BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
    Lieu CH; Klauck PJ; Henthorn PK; Tentler JJ; Tan AC; Spreafico A; Selby HM; Britt BC; Bagby SM; Arcaroli JJ; Messersmith WA; Pitts TM; Eckhardt SG
    Oncotarget; 2015 Oct; 6(33):34561-72. PubMed ID: 26439693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
    Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
    Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
    Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
    Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
    Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant HRAS as novel target for MEK and mTOR inhibitors.
    Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
    Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.
    Troiani T; Vecchione L; Martinelli E; Capasso A; Costantino S; Ciuffreda LP; Morgillo F; Vitagliano D; D'Aiuto E; De Palma R; Tejpar S; Van Cutsem E; De Lorenzi M; Caraglia M; Berrino L; Ciardiello F
    Br J Cancer; 2012 May; 106(10):1648-59. PubMed ID: 22569000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.
    Lochhead PA; Clark J; Wang LZ; Gilmour L; Squires M; Gilley R; Foxton C; Newell DR; Wedge SR; Cook SJ
    Cell Cycle; 2016; 15(4):506-18. PubMed ID: 26959608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
    Holt SV; Logie A; Davies BR; Alferez D; Runswick S; Fenton S; Chresta CM; Gu Y; Zhang J; Wu YL; Wilkinson RW; Guichard SM; Smith PD
    Cancer Res; 2012 Apr; 72(7):1804-13. PubMed ID: 22271687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
    Corcoran RB; Dias-Santagata D; Bergethon K; Iafrate AJ; Settleman J; Engelman JA
    Sci Signal; 2010 Nov; 3(149):ra84. PubMed ID: 21098728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.